Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With Ph-negative B-ALL
NCT07223190Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Jun 2028
- Primary completion
- Dec 2031
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Planned start Jun 2028; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07223190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223190.